Cloud PR Wire

Women and Alzheimers Disease Subject of Giving Tuesday Webinar

–News Direct–

Cure Alzheimers Fund will host Dr. Liisa Galea for a Giving Tuesday webinar on her research into women and Alzheimers disease. In this pre-recorded webinar, Dr. Galea presents her research on sex-based differences into the causes of Alzheimer's disease and discusses her findings with Meg Smith, CEO of Cure Alzheimer's Fund.

Dr. Liisa Galea is the Treliving Family Chair in Womens Mental Health at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada and a Professor of Psychiatry at the University of Toronto. Dr. Galea is a world-renowned expert in sex hormone influences on brain and behavior, with a focus on dementia and stress-related psychiatric disorders. Her research examines the intersection of hormones, and stress on brain plasticity in males and females.

Women develop Alzheimer's disease at twice the rate of men. Dr. Galeas research into why women are more susceptible to Alzheimers and what is driving increased risk is impressive, said CEO Smith. She is a tireless advocate for womens health research and for sex and gender-based analysis to improve cognitive aging for both women and men. We are lucky to hear from her.

There is a lot of talk about precision medicine, the idea that we can tailor treatments based on our genes. But we rarely talk about how different treatments might be needed to combat neurodegenerative diseases like Alzheimers based on our sex, said Galea. The top three risk factors for late onset sporadic Alzheimers disease include APOE4 genotype and female sex. If you are an APOE4 carrier and a female you have an even greater risk of developing Alzheimers disease than if you are male carrier. Why not harness this information to see whether we can discover new therapies to combat this devastating illness. Its time we figured out how sex plays a role, not only in the risk and progression of Alzheimers disease, but whether or not, different treatments may need to be tailored by sex.

For more information and to view the webinar, please visit Cure Alzheimers Fund at CureAlz.org and https://bit.ly/49jqQuO for the webinar.

The webinar takes place during Alzheimers Awareness Month in November. It is estimated that more than 6.5 million Americans are currently living with Alzheimers disease two-thirds of those who are afflicted are women. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimers disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones.

About Cure Alzheimers Fund

Cure Alzheimers Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimers disease. Since its founding in 2004, Cure Alzheimers Fund has provided grants to the worlds leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimers disease. Cure Alzheimers Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimers Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimers research. For more information, visit https://www.curealz.org/. To learn about our the impact of Alzheimers on women and women working towards a cure, visit https://womenandalzheimers.org.

Contact Details

Barbara Chambers

+1 978-417-9890

bchambers@curealz.org

Company Website

https://www.CureAlz.org

View source version on newsdirect.com: https://newsdirect.com/news/women-and-alzheimers-disease-subject-of-giving-tuesday-webinar-694249687

Alzheimers Disease Research Foundation

comtex tracking

COMTEX_444086634/2655/2023-11-27T07:45:34

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Marketwise Analytics journalist was involved in the writing and production of this article.